Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion type Assertion NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_head.
- NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion description "[Moreover, treatment of resistant cells with fingolimod (FTY720), a S1P receptor (S1PR) antagonist, resulted in resensitization to cetuximab both in vitro and in vivo, with inhibition of tumor growth, interference with signal transduction, induction of cancer cells apoptosis, and prolongation of mice survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_provenance.
- NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion evidence source_evidence_literature NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_provenance.
- NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion SIO_000772 23166225 NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_provenance.
- NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion wasDerivedFrom befree-20150227 NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_provenance.
- NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_assertion wasGeneratedBy ECO_0000203 NP802639.RAVVYl655b68B1ezntUi3FWEDFwFZCl4RlOqH8w_r9QBA130_provenance.